RPR115135

Known as: RPR 115135, RPR-115135 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2005
01219992005

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
It is known that the potential clinical use of farnesyltransferase inhibitors (FTI) could be expanded to include cancers… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2003
Review
2003
Oncogenic Ras proteins have been seen as an important target for novel anticancer drugs. Due to the functional role of Ras… (More)
Is this relevant?
2003
2003
A therapeutic strategy that relies on the use of c-myc antisense in combination with a farnesyltransferase inhibitor, RPR-115135… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2002
2002
A new non peptidic farnesyltransferase inhibitor, RPR-115135, in combination with 5-FU was studied in 10 human colon cancer cell… (More)
Is this relevant?
2002
2002
A new nonpeptidic farnesyltransferase inhibitor, RPR-115135, in combination with 5-fluorouracil (5-FU) was studied in an isogenic… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2001
2001
To investigate the relationship between oncogene activation and induction of micronuclei by a new non-peptidic mimetic… (More)
Is this relevant?
2001
2001
A new non peptidomimetic farnesyltransferase inhibitor, RPR-115135, was studied in an isogenic cell model system consisting of… (More)
Is this relevant?